Local immune parameters as potential predictive markers in head and neck squamous cell carcinoma patients receiving induction chemotherapy and cetuximab

The aim of this study was to determine whether tumor‐associated immune cells may predict response to therapy and disease outcome in head and neck squamous cell carcinoma (HNSCC) patients receiving induction chemotherapy and cetuximab.

[1]  É. Remenár,et al.  TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  R. Orecchia,et al.  Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II–III trial , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  S. Rottey,et al.  TILs in Head and Neck Cancer: Ready for Clinical Implementation and Why (Not)? , 2017, Head and Neck Pathology.

[4]  V. Budach,et al.  The PD‐1/PD‐L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK‐ROG) , 2017, International journal of cancer.

[5]  Tuan Bui,et al.  Multiparametric immune profiling in HPV- oral squamous cell cancer. , 2017, JCI insight.

[6]  A. Psyrri,et al.  p16, HPV, and Cetuximab: What Is the Evidence? , 2017, The oncologist.

[7]  R. Ferris,et al.  Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients , 2017, Cancer Immunology Research.

[8]  Kelvin K. W. Chan,et al.  Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review , 2017, Journal of Otolaryngology - Head & Neck Surgery.

[9]  E. Richardsen,et al.  Assessing PDL‐1 and PD‐1 in Non–Small Cell Lung Cancer: A Novel Immunoscore Approach , 2017, Clinical lung cancer.

[10]  P. Fournel,et al.  Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics , 2016, Oncotarget.

[11]  P. Fournel,et al.  Clinical and Histologic Predictive Factors of Response to Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma. , 2016, American journal of clinical pathology.

[12]  K. Harrington,et al.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. , 2016, The New England journal of medicine.

[13]  Xinxiang Li,et al.  Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer , 2016, Molecular Cancer.

[14]  J. Lunceford,et al.  Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. , 2016, The Lancet. Oncology.

[15]  R. Muschel,et al.  Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma , 2016, Oncotarget.

[16]  R. Ferris,et al.  Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients , 2016, Clinical Cancer Research.

[17]  F. Penault-Llorca,et al.  Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer , 2016, International journal of cancer.

[18]  Eva Negri,et al.  Laryngeal cancer mortality trends in European countries , 2016, International journal of cancer.

[19]  J. Carles,et al.  A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck. , 2016, International journal of radiation oncology, biology, physics.

[20]  C. Denkert,et al.  Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma , 2015, Oncotarget.

[21]  S. Hahn,et al.  The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis , 2015, Cancer research and treatment : official journal of Korean Cancer Association.

[22]  A. Ladányi,et al.  Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma , 2015, Pigment cell & melanoma research.

[23]  R. Seethala,et al.  STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients , 2015, Cancer Immunology Research.

[24]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[25]  I. Weissman,et al.  Macrophages are critical effectors of antibody therapies for cancer , 2015, mAbs.

[26]  R. Ferris,et al.  Immune biomarkers of anti-EGFR monoclonal antibody therapy. , 2015 .

[27]  Kevin P. White,et al.  Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes , 2014, Clinical Cancer Research.

[28]  L. Ding,et al.  Accumulation of CD208⁺ mature dendritic cells does not correlate with survival time in oral squamous cell carcinoma patients. , 2014, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[29]  S Michiels,et al.  Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  F. Penault-Llorca,et al.  Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  M. Rusan,et al.  The interplay between HPV and host immunity in head and neck squamous cell carcinoma , 2014, International journal of cancer.

[32]  D. Douek,et al.  PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. , 2014, The Journal of clinical investigation.

[33]  I. Çelik,et al.  Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. , 2014 .

[34]  P. Kubes,et al.  Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. , 2014, The Journal of clinical investigation.

[35]  M. Fresno,et al.  p27 and BCL2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas. , 2014, Oral Oncology.

[36]  C. Rödel,et al.  Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer , 2014, British Journal of Cancer.

[37]  E. King,et al.  Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer , 2013, British Journal of Cancer.

[38]  A. Argiris.  Current status and future directions in induction chemotherapy for head and neck cancer. , 2013, Critical reviews in oncology/hematology.

[39]  T. Nyberg,et al.  CD8+ and CD4+ tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma. , 2013, European journal of cancer.

[40]  W. Gillanders,et al.  The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer , 2013, Breast Cancer Research and Treatment.

[41]  J. Taube,et al.  Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. , 2013, Cancer research.

[42]  R. Ferris,et al.  Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients , 2013, Clinical Cancer Research.

[43]  L. Zitvogel,et al.  Trial watch , 2012, Nature Reviews Cancer.

[44]  C. Haymaker,et al.  PD-1 and BTLA and CD8+ T-cell “exhaustion” in cancer , 2012, Oncoimmunology.

[45]  H. Johansson,et al.  Tumor Infiltrating CD8+ and Foxp3+ Lymphocytes Correlate to Clinical Outcome and Human Papillomavirus (HPV) Status in Tonsillar Cancer , 2012, PloS one.

[46]  Xiaodong Li,et al.  Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer , 2012, Cancer Immunology, Immunotherapy.

[47]  É. Remenár,et al.  8533 POSTER First Results of an Uncontrolled, Phase II Trial of Induction Chemotherapy With Cetuximab and Docetaxel-Cisplatin-5FU Followed by Cetuximab+Radiotherapy in the Responders in Locally Advanced Resectable Squamous Cell Cancer of the Head and Neck , 2011 .

[48]  J. Tímár,et al.  Prognostic impact of B-cell density in cutaneous melanoma , 2011, Cancer Immunology, Immunotherapy.

[49]  R. Ferris,et al.  Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity , 2011, Immunologic research.

[50]  G. D. de Bock,et al.  The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis , 2011, British Journal of Cancer.

[51]  C. Denkert,et al.  Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy , 2011, Seminars in Immunopathology.

[52]  Laurence Zitvogel,et al.  Immune parameters affecting the efficacy of chemotherapeutic regimens , 2011, Nature Reviews Clinical Oncology.

[53]  S. Rosenberg,et al.  Selection of CD8+PD-1+ Lymphocytes in Fresh Human Melanomas Enriches for Tumor-reactive T Cells , 2010, Journal of immunotherapy.

[54]  Soldano Ferrone,et al.  Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  C. la Vecchia,et al.  The oral cancer epidemic in central and eastern Europe , 2010, International journal of cancer.

[56]  I. Salmon,et al.  Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients , 2010, BMC Cancer.

[57]  J. Tímár,et al.  FOXP3+ Cell Density in Primary Tumor Has No Prognostic Impact in Patients with Cutaneous Malignant Melanoma , 2010, Pathology & Oncology Research.

[58]  S. Rosenberg,et al.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. , 2009, Blood.

[59]  T. Dønnem,et al.  Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[60]  L. Zitvogel,et al.  The anticancer immune response: indispensable for therapeutic success? , 2008, The Journal of clinical investigation.

[61]  T. Gorlia,et al.  Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. , 2007, The New England journal of medicine.

[62]  J. Tímár,et al.  Association of microvessel density with infiltrating cells in human cutaneous malignant melanoma , 2007, Pathology & Oncology Research.

[63]  J. Cheville,et al.  PD-1 Is Expressed by Tumor-Infiltrating Immune Cells and Is Associated with Poor Outcome for Patients with Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[64]  J. Tímár,et al.  Density of DC-LAMP+ mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor , 2007, Cancer Immunology, Immunotherapy.

[65]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[66]  E. Tartour,et al.  Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers , 2006, Clinical Cancer Research.

[67]  L. Zitvogel,et al.  Trial watch , 2012, Oncoimmunology.

[68]  B. Döme,et al.  Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  J. Tímár,et al.  T-Cell Activation Marker Expression on Tumor-Infiltrating Lymphocytes As Prognostic Factor in Cutaneous Malignant Melanoma , 2004, Clinical Cancer Research.

[70]  R. Day,et al.  The number of intratumoral dendritic cells and ζ‐chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma , 2001, Cancer.

[71]  Mechthild Krause,et al.  CD8+ tumour‐infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK‐ROG) , 2016, International journal of cancer.

[72]  T. O’Toole,et al.  Myeloid cells as effector cells for monoclonal antibody therapy of cancer. , 2014, Methods.

[73]  Patrice Ravel,et al.  PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. , 2013, Cancer research.

[74]  Carsten Denkert,et al.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  M. Kloor,et al.  The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. , 2009, Cancer immunity.